Syros Pharmaceuticals (NASDAQ:SYRS) Downgraded by StockNews.com to Sell

StockNews.com downgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a hold rating to a sell rating in a research note released on Wednesday.

Other analysts have also recently issued reports about the company. HC Wainwright reaffirmed a buy rating and set a $15.00 price objective on shares of Syros Pharmaceuticals in a research report on Monday, April 1st. Piper Sandler reaffirmed an overweight rating and set a $13.00 price objective on shares of Syros Pharmaceuticals in a research report on Wednesday, April 3rd.

Syros Pharmaceuticals Stock Performance

Shares of NASDAQ:SYRS opened at $5.11 on Wednesday. Syros Pharmaceuticals has a 1 year low of $2.09 and a 1 year high of $8.17. The company has a debt-to-equity ratio of 2.07, a quick ratio of 3.95 and a current ratio of 3.95. The stock’s 50-day moving average is $6.34 and its 200 day moving average is $5.19.

Institutional Trading of Syros Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Syros Pharmaceuticals by 44.8% in the 4th quarter. Vanguard Group Inc. now owns 764,812 shares of the company’s stock worth $5,958,000 after purchasing an additional 236,620 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Syros Pharmaceuticals by 125.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 239,681 shares of the company’s stock worth $1,867,000 after purchasing an additional 133,149 shares in the last quarter. Blue Owl Capital Holdings LP bought a new stake in shares of Syros Pharmaceuticals in the 4th quarter worth approximately $11,632,000. Opaleye Management Inc. bought a new stake in shares of Syros Pharmaceuticals in the 4th quarter worth approximately $2,799,000. Finally, Flagship Pioneering Inc. boosted its position in shares of Syros Pharmaceuticals by 30.2% in the 4th quarter. Flagship Pioneering Inc. now owns 1,293,848 shares of the company’s stock worth $10,079,000 after purchasing an additional 300,000 shares in the last quarter. 91.47% of the stock is owned by institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.